Combination of preoperative tumour markers and lymphovascular invasion with TNM staging as a cost and labour efficient subtyping of colorectal cancer

Tomoki Yamano1✉, Shinichi Yamauchi2, Masataka Igeta3, Yuya Takenaka1, Jihyung Song1, Kei Kimura1, Michiko Yasuhara1, Akihito Babaya1, Kozo Kataoka5, Naohito Beppu1, Masataka Ikeda1, Naohiro Tomita1 & Kenichi Sugihara2

Tumour-Node-Metastasis (TNM) staging of colorectal cancer (CRC) needs further classification for better treatment because of disease heterogeneity. Although molecular classifications which are expensive and laborious are under study, cost and labour efficient subtyping is desirable. We assessed the combinations of preoperative tumour marker (tM) elevation and tumour lymphovascular invasion (LVI) as a solution. We used the pooled data of 7151 colon cancer (CC) patients and 4620 rectal cancer (RC) patients who received curative surgery between 2004 and 2008 in Japan. The best-matched subtyping for predicting relapse-free survival (RFS) was statistically selected using the c-index and Akaike’s information criterion. This subtyping (tM-LVI), which consisted of three categories by tM elevation status and severity of LVI status, was an independent prognostic factor for RFS of CC (stage IIA, IIB, and IIIC) and RC (stage I, IIA, IIB, IIIB, and IIIC) and also for disease specific survival of CC (stage IIa, IIb, IIIb, and IIIc) and RC (all stage except for IIc). Although TM-LVI classified CRC patients into low and high recurrence risk groups, the application of adjuvant therapy was not accordance with the tM-LVI status. TM-LVI may be a cost and labour efficient subtyping of colorectal cancer for better treatment strategy.

The treatments of colorectal cancer (CRC) patients after curative surgery are based on clinical staging. CRC patients with high risk stages (i.e., stages II and III) are recommended for adjuvant therapy1–5. However, the heterogeneous characteristics of CRC results in different prognoses among CRC patients within the same clinical stage. As a result, both the American Joint Committee on Cancer/Union for International Cancer Control staging system (Tumour-Node-Metastasis [TNM] staging system) and the Japanese Society for Cancer of the Colon and Rectum (JSCCR) staging system have developed several editions to improve the accuracy of predicting prognosis6–8. These staging systems are composed of tumour depth, nodal status, and metastatic status, although there are differences among the versions even in the same staging system. Therefore, further subtyping in each clinical stage is indispensable for better treatment strategy.

Recently, classifications of CRC using genetic background have been proposed as alternative or additional tools for staging. Microsatellite instability (MSI) status indicated good prognosis in patients with stage II/III right-sided colon cancer (CC)9. Consensus molecular subtypes consisting of four groups (MSI immune, canonical, metabolic, and mesenchymal) have been presented as powerful tools for CRC biology and treatment10–13. These classifications based on genetic analysis have been expected to replace TNM staging in the future, although benefit for treatment decision has not been validated.

1Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan. 2Division of Colorectal Surgery, Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan. 3Department of Biostatistics, Hyogo College of Medicine, Hyogo, Japan. ✉e-mail: yamanot@hyo-med.ac.jp
However, high risk patients for recurrence have been selected using clinicopathological features. Many articles have demonstrated that elevations in tumour markers (TMs, e.g., carcinoembryonic antigen [CEA] or cancer antigen 19-9 [CA19-9]) have been associated with poor prognosis in CRC14–18. Lymphovascular invasion (LVI) was also indicated to be a prognostic factor for CRC 19–22. However, these factors have not been included in the TNM staging systems and have not been assessed in combination. We considered that improvement of classification by combination of these features was necessary before applying novel classifications that require more labour and cost.

Thus, we statistically selected the most suitable subtyping combined the influence of TM elevation and LVI on relapse-free survival (RFS) using the pooled data collected by the Japanese Study Group for Postoperative Follow-up of CRC (JFUP-CRC), which is one of the largest data collections in Japan23,24. We evaluated this classification (so called TM-LVI) as a prognostic factor for RFS and disease specific survival (DSS) in each TNM staging. We also assessed the association between application of adjuvant therapy and TM-LVI status.

Results
Clinicopathological characteristics of the patients. Clinicopathological characteristics were compared between CC and rectal cancer (RC) patients. There were significant differences between CC and RC patients in age ($P<0.0001$), sex ($P<0.0001$), histological type ($P<0.0001$), the degree of LVI ($P<0.0001$), dissected lymph node number ($12 \leq$ or not), TNM stage ($P<0.0001$), and the application of adjuvant therapy ($P<0.0001$) but not in the ratio of CA19-9 elevation (Supplementary Table 1).

Adjuvant therapy consisted of chemotherapy except for two cases of radiotherapy and seven cases of chemoradiotherapy in RC. Most patients (94.6%) received 5-fluorouracil based chemotherapy. A total of 1.6% and 1.1% of the patients received oxaliplatin-based and irinotecan-based chemotherapy, respectively (Supplementary Table 1).

Thus, further analysis was performed by CC and RC.

Selection of the most suitable subtyping. Among six candidate subtypes (Table 1), ABC1 was the most statistically suitable subtype with the lowest Akaike's information criterion (AIC, Supplementary Table 2) and the highest Harrell's concordance index (c-index, Supplementary Table 3) according to the models including TNM staging.
Figure 2. Disease free survival (DSS) of colon cancer (a–f) and rectal cancer (g–l) patients by TM-LVI status is shown for each TNM stage. The 5-year DSS rate is described on the right of the TM-LVI status. Bold type, P < 0.05; Red circle, difference of DSS rate among TM-LVI statuses > 20%.

Table 1. Candidate subtypes were determined depending on the tumour marker elevation status and lymphovascular invasion status. CA19-9, Cancer antigen 19-9; CEA, Carcinoembryonic antigen.
Table 2. Univariate and multivariate analysis for relapse-free survival of colon cancer was performed in each clinical stage. TM-LVI was an independent prognostic factor for relapse-free survival of colon cancer in stage IIa, IIb, and IIc. M/F, Male/Female; Diff/Undiff, Differentiated/Undifferentiated; LN, Lymph node; RR, Risk ratio; Bold type, \( P < 0.05 \).

| Stage | I | IIa | IIb | IIc | IIIa | IIIb | IIIc |
|-------|---|-----|-----|-----|------|------|------|
|       | RR | P   | RR | P   | RR | P   | RR | P   | RR | P   | RR | P   | RR | P   | RR | P   |
| Age   | 75 \( \geq 75 \) | 0.97 | 0.94 | 1.22 | 0.21 | —  | —  | 1.3 | 0.29 | 1.63 | 0.10 | 1.02 | 0.97 | 1.12 | 0.30 | —  | —  | 1.12 | 0.50 |
|       | Gender | M/F | 1.53 | 0.20 | 1.25 | 0.14 | —  | —  | 0.96 | 0.84 | 1.04 | 0.88 | 0.93 | 0.86 | 1.29 | 0.01 | 1.29 | 0.01 | 1.21 | 0.17 | 1.21 | 0.16 |
|       | Histology | Diff/Undiff | 0.94 | 0.95 | 6.26 | 0.0003 | 6.11 | 0.0004 | 1.51 | 0.34 | 0.88 | 0.78 | 0.61 | 0.53 | 1.11 | 0.60 | —  | —  | 0.95 | 0.76 |
|       | Dissected LN | 12 \( > / < 12 \) | 0.89 | 0.71 | 1.54 | 0.01 | 1.42 | 0.11 | 1.37 | 0.27 | 2.13 | 0.03 | 0.99 | 0.97 | 1.41 | 0.008 | 1.36 | 0.06 | 1.30 | 0.30 |
|       | Adjuvant | Yes/No | 6.25 | 0.002 | 1.01 | 0.98 | —  | —  | 1.39 | 0.19 | 0.80 | 0.53 | 0.82 | 0.62 | 0.94 | 0.55 | —  | —  | 0.92 | 0.57 |
|       | TM-LVI | C/A | 1.9 \( \times 10^{-7} \) | 2.31 | <0.0001 | 2.32 | 1.80 | 1.79 | 0.98 | 2.84 | <0.0001 | 1.69 | <0.0001 | 1.19 | 1.41 | 1.60 | 1.60 |
|       |       | B/A | 0.96 | 0.42 | 1.60 | 1.54 | 0.0001 | 1.03 | 0.08 | 0.91 | 0.14 | 2.17 | 0.19 | 1.70 | 0.008 | 1.36 | 0.06 | 1.30 | 0.30 |
|       |       | C/B | 2.1 \( \times 10^{-6} \) | 1.44 | 1.50 | 1.75 | 1.95 | 0.45 | 1.66 | 1.68 | 1.61 | 1.60 | 1.60 |

Table 3. Univariate and multivariate analysis for relapse-free survival of rectal cancer was performed in each clinical stage. TM-LVI was an independent prognostic factor for relapse-free survival of rectal cancer in stage I, IIa, IIb, and IIc. M/F, Male/Female; Diff/Undiff, Differentiated/Undifferentiated; LN, Lymph node; RR, Risk ratio; Bold type, \( P < 0.05 \).

| Stage | I | IIa | IIb | IIc | IIIa | IIIb | IIIc |
|-------|---|-----|-----|-----|------|------|------|
|       | RR | P   | RR | P   | RR | P   | RR | P   |
| Age   | 75 \( \geq 75 \) | 1.66 | 0.048 | 1.52 | 0.10 | 1.16 | 0.43 | —  | —  | 0.92 | 0.83 | 0.86 | 0.77 | 2.36 | 0.028 | 1.74 | 0.16 | 1.09 | 0.35 | —  | —  | 0.95 | 0.85 |
|       | Gender | M/F | 0.84 | 0.38 | —  | —  | 1.27 | 0.12 | —  | —  | 0.90 | 0.71 | 1.37 | 0.35 | 1.79 | 0.07 | —  | —  | 1.27 | 0.03 | 1.24 | 0.054 | 1.13 | 0.39 |
|       | Histology | Diff/Undiff | 1.04 | 0.96 | —  | —  | 0.97 | 0.94 | —  | —  | 0.51 | 0.19 | 0.45 | 0.14 | 0.43 | 0.12 | 0.31 | 0.056 | 1.06 | 0.83 | —  | —  | 0.64 | 0.049 |
|       | Dissected LN | 12 \( > / < 12 \) | 1.38 | 0.13 | —  | —  | 1.11 | 0.55 | —  | —  | 1.54 | 0.2 | 1.86 | 0.24 | 0.98 | 0.95 | 1.60 | 0.0007 | 1.54 | 0.007 | 0.85 | 0.90 |
|       | Adjuvant | Yes/No | 1.99 | 0.089 | —  | —  | 1.46 | 0.029 | 1.56 | 0.07 | 1.27 | 0.44 | 1.00 | 0.42 | 0.006 | 0.53 | 0.053 | 0.75 | 0.014 | 0.76 | 0.02 | 0.90 | 0.56 |
|       | TM-LVI | C/A | 3.40 | <0.0001 | 3.24 | 0.0002 | 2.66 | <0.0001 | 2.59 | <0.0001 | 2.98 | 0.0004 | 3.32 | 0.0003 | 1.08 | 0.74 | 0.50 | 2.33 | 0.0005 | 2.13 | <0.0001 | 1.32 | <0.0001 | 0.84 | 0.06 |
|       |       | B/A | 2.28 | <0.0001 | 2.24 | 0.0002 | 2.40 | <0.0001 | 1.77 | <0.0001 | 1.88 | 0.0004 | 8.98 | 0.0003 | 0.95 | 0.74 | 0.50 | 2.33 | 0.0005 | 2.13 | <0.0001 | 1.32 | <0.0001 | 0.84 | 0.06 |
|       |       | C/B | 1.49 | 0.38 | 1.48 | 1.47 | 3.38 | 3.30 | 1.65 | 2.41 | 1.71 | 1.56 | 1.56 | 1.54 |

Validation of TM-LVI for RFS and DSS. Log-rank test demonstrated that RFS was significantly different by TM-LVI status in CC (stage IIa, IIb, and IIc) and RC (stage I, IIa, IIb, IIIa, IIIb) (Fig. 1). In particular, the 5-year RFS differed more than 20% by TM-LVI status between A and C (83.7% and 62.1% in stage IIIb of CC, staging. Then, we called ABC1 as TM-LVI. Both TNM and TM-LVI were significant in the Cox model for RFS in CC and RC patients. The interaction term between TNM and TM-LVI was significant in RC but not CC. Thus, in ranking the incidence rate of RFS, the main effect model with TNM and TM-LVI was applied to CC, and the interaction model was employed for RC. When RFS was ranked from 1st to 21st by TNM staging and TM-LVI, RFS was not ordered by TNM staging. Stage IIIa was a low recurrence risk group compared to most of stage II, and stage IIIc also had the lowest recurrence risk group compared to most of stage II.
| Stage    | I   | IIA | IIb | IIc | IIA | IIb | IIc |
|-------|-----|-----|-----|-----|-----|-----|-----|
| Factors | Univariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|       | RR   | P   | RR  | P   | RR  | P   | RR  | P   |
| Age   | 75≥<75 | 1.13 | 0.83 | 2.21 | 0.0006 | 2.01 | 0.0025 |
| Gender | M/F  | 1.58 | 0.44 | 0.14 | 0.80 | 0.49 |
| Histology | Diff/Undiff | 6.8×10³ | 0.44 | 5.23 | 0.026 | 4.67 | 0.04 |
| Dissected LN | 12>12≤ | 0.65 | 0.64 | 2.64 | 0.0002 | 2.21 | 0.004 |
| Adjuvant | Yes/No | 1.5×10⁻⁴ | 0.43 | 0.62 | 0.19 | 1.47 | 0.28 |
| TM-LVI | C/A   | 1.6×10⁻⁺ | 2.85 | 2.80 | 3.68 | 3.47 | 2.29 |
|        | B/A   | 1.6×10⁻⁺ | 2.25 | 2.04 | 0.009 | 1.35 | 0.003 |
|        | C/B   | 1.0   | 1.27 | 1.37 | 2.41 | 2.30 | 1.66 |

Table 4. Univariate and multivariate analysis for disease specific survival of colon cancer was performed in each clinical stage. TM-LVI was an independent prognostic factor for relapse-free survival of colon cancer in stage IIA, IIb, IIB, and IIIc. M/F, Male/Female; Diff/Undiff, Differentiated/Undifferentiated; LN, Lymph node; RR, Risk ratio; Bold type, P < 0.05.

76.6% and 47.9% in stage IIB of RC, 91.6% and 63.3% in stage IIIa of RC, and 76.5% and 56.4% in stage IIB of RC). Log-rank test also demonstrated that DSS was significantly different by TM-LVI in CC (stage IIA, IIb, IIb, and IIIc) and RC (except for IIC) (Fig. 2). The 5-year DSS differed more than 20% by TM-LVI status between A and C (82.9% and 54.3% in stage IIIC of CC and 91.9% and 69.3% in stage IIIb of RC).

We assessed the factors associated with RFS and DSS by univariate and multivariate analysis. TM-LVI was an independent prognostic factor for RFS of CC (stage IIA, IIb, and IIIc, Tables 1, 2) and RC (stage I, IIa, IIb, IIIa, and IIb, Table 3) and also for DSS of CC (stage IIA, IIb, IIb, and IIIc, Table 4) and RC (all stage except for IIC, Table 5).

**Association between the adjuvant therapy and TM-LVI status.** The application of adjuvant therapy significantly differed by TM-LVI in stage I, IIb, IIA, and IIc CC and stage IIC RC (Table 6). However, the application of adjuvant therapy was not irrelevant with the recurrence risk evaluated by TM-LVI except for stage IIA CC. The application of adjuvant therapy did not differ by TM-LVI status (stage IIIC CC and in stage I, IIa, IIb, and IIb RC) or adversely decreased in spite of the increased recurrence (stage IIIC CC and stage IIIb RC), although TM-LVI status was an independent prognostic factor for both RFS and DSS in these stages. These results suggested that TM-LVI, which represents tumour marker elevation and lymphovascular invasion, was not used for determining the use of adjuvant treatment.

**Discussion**

Due to the heterogeneity of the disease, further classification beyond TNM-based clinical staging has been considered indispensable for determining the treatment strategy of CRC. Despite continued effort, novel modalities are still under development. We combined TM elevation and LVI for subtyping of the TNM staging system because of their potential as prognostic factors and ready-to-use availability. Among candidate classifications, we selected the most statistically suitable classification and named TM-LVI.

Our data demonstrated that TM-LVI was useful for subtyping and prognosis for not only RFS but also DSS, although we picked up TM-LVI depending on RFS. This may be consistent with the fact that TM elevation and LVI have been considered prognostic factors for RFS and overall survival, respectively.

Our data indicated that adjuvant treatment was not considered in accordance with the recurrence risk determined by TM-LVI status. Thus, TM-LVI may be useful for considering adjuvant therapy after curative surgery when TM-LVI is an independent prognostic factor for both RFS and DSS (stage IIA, IIb, and IIc CC and stage I, IIa, IIb, IIIa, and IIIb RC).

We evaluated LVI by scoring both lymphatic invasion and venous invasion, although LVI is usually discussed as positive or negative. This may be because pathological assessments differ among pathologists regarding LVI status. Our data indicated that adjuvant treatment was not considered in accordance with the recurrence risk determined by TM-LVI status.
Table 5. Univariate and multivariate analysis for disease specific survival of rectal cancer was performed in each clinical stage. TM-LVI was an independent prognostic factor for relapse-free survival of rectal cancer in stage I, IIa, IIb, IIIb, and IIIc. M/F, Male/Female; Diff/Undiff, Differentiated/Undifferentiated; LN, Lymph node; RR, Risk ratio; Bold type, P < 0.05.

In conclusion, we present a cost and labour efficient subtyping method (TM-LVI) for CRC patients using clinicopathological features routinely assessed in the clinic all over the world. The usefulness of TM-LVI should be validated in the future by randomized clinical trials regarding adjuvant treatment after curative surgery for patients with poor prognosis as estimated by TM-LVI.

Methods

Patients and data collection. The JFUP-CRC contains data from twenty-three institutes in Japan (Sapporo Medical University Hospital, Hirosaki University Hospital, Niigata University Hospital, Niigata Cancer Center Hospital, National Defence Medical College Hospital, Tochigi Cancer Center Hospital, Tokyo University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, National Cancer Center Hospital, Tokyo Women's Medical University Hospital, National Center for Global Health and Medicine Hospital, Tokyo Medical and Dental University Hospital, Keio University Hospital, Teikyo University Hospital, Kyorin University Hospital, Kitasato University Hospital, Fujita Health University Hospital, Aichi Cancer Center Hospital, Kyoto University Hospital, Osaka International Cancer Institute Hospital, Osaka Rosai Hospital, Hyogo College of Medicine Hospital, and Kurume University Hospital). Each hospital retrospectively collected the clinical data of patients with CRC who underwent curative surgery. This study was approved by the institutional review board or ethics committee at all 23 hospitals above and was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Clinical Research. The patients provided written informed consent, and patients had the option to opt-out if there was any disagreement with this study. The JFUP-CRC office pooled and organized the data for this study. Among the patients whose data are contained in the database, we assessed 11771 patients, consisting of 7151 CC patients and 4620 RC patients, who received curative surgery between 2004 and 2008. We classified these patients by the 8th edition TNM staging system6,7. A higher level of CEA or CA19-9 than the upper limit in each hospital was determined to indicate TM elevation. TM elevation was classified into three categories: both CEA and CA19-9 elevation, either CEA or CA19-9 elevation, or no elevation. Lymphatic or venous invasion was evaluated as 0 (no invasion), 1 (minimal invasion), 2 (moderate invasion), or 3 (severe invasion) by pathologists in each hospital according to the classification by the JSCCR8. We summed the evaluation in both lymphatic invasion and venous invasion as LVI, which was categorized as none (0), slight (1-2), mild (3-4), or severe (5-6).

Selection of the most suitable subtyping. To select the most suitable subtyping using both TM elevation and LVI, we assessed six candidate classifications (ABC1-ABC5, AB), which simplified 12 categories determined by TM elevation (both, either, or none) and LVI (none, slight, mild, or severe) into three (A, B, and C; ABC1-ABC5) or two (A, B; AB) subtypes (Table 1). Then, Akaike's information criterion (AIC) and Harrell's concordance index (c-index) were derived from the Cox proportional hazard model with TNM and each subtype to explore the most suitable (lower AIC and/or higher c-index) subtyping for RFS. If the interaction term between TNM and the candidate classification was significant, the term was included in the Cox model for ranking the incidence rates of RFS within each subtype. We did not exclude the patients who received adjuvant therapy, because we explored the subtyping available in all patients who received curative surgery.
Validation of TM-LVI for RFS and DSS. Univariate analysis was performed using Cox proportional hazard model, along with age (75 ≤ or not), sex, histological type (differentiated type or not), number of dissected lymph nodes (12 ≤ or not), and adjuvant therapy. Multivariate analysis was also performed using Cox proportional hazard model with the factors that showed significant differences (p < 0.05) in the univariate analysis. When TM-LVI was the only significant factor in the univariate analysis, multivariate analysis was performed using Cox proportional hazard model using the factors with p < 0.02. The influence of TM-LVI on RFS and DSS in each TNM stage was also assessed by Kaplan-Meier curve and evaluated by the Log-rank test.

Data analysis. The comparisons of the clinicopathological characteristics between CC and RC patients were assessed by the chi-squared test or t-test. The influence of the clinicopathological features on RFS and DSS was calculated by the Kaplan-Meier method and compared by the log-rank test. Differences in the application of adjuvant therapy by combined subtyping were evaluated by the chi-squared test. Multivariate analysis for RFS and DSS was performed using a Cox proportional hazard model, along with age (75 ≤ or not), sex, histological type (differentiated type or not), number of dissected lymph nodes (12 ≤ or not), and adjuvant therapy. Multivariate analysis was also performed using Cox proportional hazard model for stage IIa CC. Red circles indicated that TM-LVI was an independent prognostic factor for both relapse-free survival and disease specific survival. Adjuvant therapy may be recommended according to TM-LVI status in these stages. Bold type, P < 0.05.

Table 6. Association between the adjuvant therapy and TM-LVI status was assessed in each clinical stage. The application of adjuvant therapy was not related to the risk of recurrence as estimated by TM-LVI status except for stage Ia CC. Red circles indicated that TM-LVI was an independent prognostic factor for both relapse-free survival and disease specific survival. Adjuvant therapy may be recommended according to TM-LVI status in these stages. Bold type, P < 0.05.

| Location | TNM stage | TM-LVI | A Number (%) | B Number (%) | C Number (%) | P      |
|----------|-----------|--------|--------------|--------------|--------------|--------|
| Colon    | I         |        | 35(2.1%)     | 5(2.0%)      | 48(5.5%)     | 0.013  |
|          | Ia        | 148(11.3%) | 85(14.1%)     | 44(18.5%)    |             | 0.0054 |
|          | Ib        | 44(23.4%) | 33(21.3%)     | 17(19.8%)    |             | 0.77   |
|          | Ic        | 15(19.5%) | 14(21.2%)     | 11(22.9%)    |             | 0.90   |
|          | IIIa      | 145(67.1%) | 46(62.2%)     | 5(31.3%)     |             | 0.014  |
|          | IIIb      | 398(61.1%) | 401(66.7%)    | 261(62.3%)   |             | 0.10   |
|          | IIIc      | 58(80.6%) | 112(70.9%)    | 130(63.4%)   |             | 0.0003 |
| Rectum   | I         | 45(3.9%) | 14(6.3%)      | 2(4.0%)      |             | 0.25   |
|          | Ia        | 86(14.8%) | 85(19.4%)     | 37(21.1%)    |             | 0.059  |
|          | Ib        | 12(20.7%) | 26(34.2%)     | 11(22.5%)    |             | 0.16   |
|          | Ic        | 9(26.5%)  | 8(26.7%)      | 13(44.8%)    |             | 0.22   |
|          | IIa       | 15(77.8%) | 72(73.5%)     | 11(52.4%)    |             | 0.036  |
|          | IIb       | 272(73.5%) | 293(72.7%)    | 225(68.8%)   |             | 0.34   |
|          | IIc       | 34(66.7%) | 68(75.6%)     | 117(75.0%)   |             | 0.45   |

References
1. André, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109–3116 (2009).
2. Labianca, R. et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), v66–72 (2013).
3. NCCN. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines) version1. 2019 colon cancer. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
4. NCCN. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines) version1. 2019 rectal cancer. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
5. Iveson, T. J. et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 19, 562–578 (2018).
6. Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. TNM classification of malignant tumours. 8th ed. (JOHN WILEY & SONS LTD. 2017).
7. Amin, M. B. et al. AJCC Cancer Staging Manual, 8th Edition. (Springer International Publishing, 2017).
8. Japanese Classification of Colorectal Carcinoma by Japanese Society for Cancer of the Colon and rectum, Second English edition. Tokyo (Kanehara, 2009).
9. Sinicrope, F. A. et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J. Clin. Oncol. 31, 3664–3672 (2013).
10. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
11. Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer. 17, 79–92 (2017).
12. Wang, W. et al. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Semin. Cancer Biol. 55, 37–52 (2019).
13. Fontana, E., Eason, K., Cervantes, A., Salazar, R. & Sadanandam, A. Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann. Oncol. 30, 520–527 (2019).
14. Park, J. I., Choi, G. S., Lim, K. H., Kang, B. M. & Jun, S. H. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. *Ann. Surg. Oncol.* 16, 3087–3093 (2009).
15. Lin, P. C. et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. *Int. J. Colorectal Dis.* 27, 1333–1338 (2012).
16. Shibutani, M. et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. *Anticancer Res.* 34, 3753–3758 (2014).
17. Kim, C. G. et al. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. *Ann. Surg. Oncol.* 24, 227–235 (2017).
18. Yu, Z., Chen, Z., Wu, J., Li, Z. & Wu, Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. *PLoS One.* 12, e0188139 (2017).
19. Huh, J. W., Lee, J. H., Kim, H. R. & Kim, Y. J. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. *Am. J. Surg.* 206, 758–763 (2013).
20. Nikberg, M. et al. Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. *Acta Oncol.* 55, 1418–1424 (2016).
21. Yuan, H. et al. Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis. *Acta Oncol.* 8, 46565–46579 (2017).
22. Jiang, H. H. et al. Prognostic significance of lymphovascular invasion in colorectal cancer and its association with genomic alterations. *World J. Gastroenterol.* 25, 2489–2502 (2019).
23. Yamano, T. et al. Evaluation of appropriate follow-up after curative surgery for patients with colorectal cancer using time to recurrence and survival after recurrence: a retrospective multicenter study. *Oncotarget.* 9, 25474–25490 (2018).
24. Yamano, T. et al. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. *Eur. J. Cancer.* 81, 90–101 (2017).
25. Yamano, T. et al. Management strategies in Lynch syndrome and familial adenomatous polyposis: a national healthcare survey in Japan. *Cancer Sci.* 108, 243–249 (2017).

Acknowledgements

We appreciate the following members of the JFUP-CRC who provided the data: I. Takemasa (Sapporo Medical University), K. Hakamada (Hirosaki University), H. Kameyama (Niigata University), Y. Takii (Niigata Cancer Center Hospital), K. Hase (National Defence Medical College), H. Ozawa (Tochigi Cancer Center), H. Nozawa (Tokyo University), K. Takahashi (Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital), Y. Kanemitsu (National Cancer Center Hospital), M. Itabashi (Tokyo Women’s Medical University), H. Yano (National Center for Global Health and Medicine), Y. Kinugasa (Tokyo Medical and Dental University), H. Hasegawa (Keio University), Y. Hashiguchi (Teikyo University), T. Masaki (Kyorin University), M. Watanabe (Kitasato University), T. Hanai (Fujita Health University), K. Komori (Aichi Cancer Center Hospital), Y. Sakai (Kyoto University), M. Ohue (Osaka International Cancer Institute), S. Noura (Osaka Rosai Hospital), and Y. Akagi (Kurume University). We also appreciate American Journal Experts for editing our manuscript. Funding this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

T.Y.: Conception, study design, data analysis, acquisition of data, and manuscript writing; S. Y.: Data analysis and acquisition of data. M.I.: Statistical data analysis and manuscript writing. Y.T., J.S., K.K., M.Y., A.B., K.K., N.B., M.I., N.T. and K.S.: Data analysis and acquisition of data, All authors reviewed and approved the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-66652-z.

Correspondence and requests for materials should be addressed to T.Y.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020